（原标题：18只ETF公告上市，最高仓位54.18%） 华安恒生港股通科技主题ETF今日发布上市公告书，基金将于2025年8月25日上市，上市交易份额为14.53亿份，该基金成立日为2025年8月14日， 截至2025年8月18日，基金投资组合中，银行存款和结算备付金合计占基金总资产的比例为84.72%，股票投资占基金总资产的比例为15.26%，目 前基金仍处于建仓期。 证券时报•数据宝统计，8月以来共有18只股票型ETF公告上市，平均仓位仅为24.50%，仓位最高的是嘉实恒生港股通科技主题ETF，仓位为 54.18%，仓位居前的还有科创200ETF工银、鹏华国证机器人产业ETF、汇添富国证港股通互联网ETF，仓位分别为52.40%、45.43%、37.46%，仓 位较低的为兴业科创价格ETF、科创50ETF东财、兴业中证全指自由现金流ETF，仓位分别为0.00%、0.00%、9.45%。 一般来说，ETF上市都要满足基金合同规定的仓位要求，发布上市公告书，距离正式上市时间会差几个交易日，其间如果仓位较低，会在上市前 完成建仓。 8月以来公告上市的ETF中，按上市交易份额统计，平均募集4.43亿份，规模居前的 ...

Summary of Key Points Core Viewpoint - On August 13, the total net inflow of cross-border ETFs reached 906 million yuan, with a cumulative net inflow of 20.62 billion yuan over the past five trading days, indicating strong investor interest in these funds [1]. Fund Inflows - A total of 40 cross-border ETFs experienced net inflows on August 13, with the top performer being the GF CSI Hong Kong Stock Connect Non-Bank ETF (513750), which saw an increase of 528 million shares and a net inflow of 906 million yuan [1][3]. - The GF CSI Hong Kong Stock Connect Non-Bank ETF had a latest scale of 14.879 billion yuan, reflecting a 1.78% increase in value [3]. Fund Outflows - Conversely, 50 cross-border ETFs recorded net outflows on the same day, with the leading outflow being the E Fund China Concept Internet 50 ETF (513050), which saw a reduction of 309 million shares and a net outflow of 454 million yuan [4][5]. - The E Fund China Concept Internet 50 ETF had a latest scale of 33.942 billion yuan, with a 4.06% increase in value despite the outflow [5]. Performance Overview - The top 10 ETFs by net inflow included several funds focused on technology and healthcare sectors, indicating a trend towards these industries among investors [3][5]. - The top 10 ETFs by net outflow highlighted a mix of technology and healthcare funds, suggesting a potential shift in investor sentiment or profit-taking in these areas [4][5].

近期成立的股票ETF基金建仓期仓位 （文章来源：证券时报网） | 基金代 | 基金简称 | 基金成立 | 募集规模 | 上市公告数据 | 上市公告书披露股 | 上市日期 | | --- | --- | --- | --- | --- | --- | --- | | 码 | | 日 | （亿份） | 截止日期 | 票仓位（%） | | | 159277 | 富国中证港股通高股 | 2025.08.05 | 2.42 | 2025.08.07 | 33.54 | 2025.08.14 | | | 息投资ETF | | | | | | | 589850 | 科创50ETF东财 | 2025.08.01 | 7.54 | 2025.08.04 | 0.00 | 2025.08.11 | | 520970 | 嘉实中证港股通创新 | 2025.07.30 | 8.90 | 2025.07.31 | 16.11 | 2025.08.07 | | | 药ETF | | | | | | | 159278 | 鹏华国证机器人产业 | 2025.07.30 | 3.89 | 2025.08.05 | 45.43 | 2025.0 ...

科创200ETF工银今日发布上市公告书，基金将于2025年8月8日上市，上市交易份额为6.17亿份，该基 金成立日为2025年7月23日，截至2025年8月1日，基金投资组合中，银行存款和结算备付金合计占基金 总资产的比例为34.67%，股票投资占基金总资产的比例为52.40%，目前基金仍处于建仓期。 近一个月公告上市的ETF中，按上市交易份额统计，平均募集4.65亿份，规模居前的有富国中证港股通 科技ETF、嘉实中证港股通创新药ETF、南方创业板中盘200ETF等，份额分别为11.19亿份、8.90亿份、 7.99亿份。 证券时报·数据宝统计，近一个月共有29只股票型ETF公告上市，平均仓位仅为21.60%，仓位最高的是 科创200ETF工银，仓位为52.40%，仓位居前的还有汇添富国证通用航空产业ETF、鹏华科创板芯片 ETF、汇添富中证沪港深云计算产业ETF，仓位分别为42.30%、39.29%、35.63%，仓位较低的为博时恒 生港股通创新药精选ETF、天弘中证A100ETF、富国中证港股通科技ETF，仓位分别为0.00%、0.00%、 9.16%。 一般来说，ETF上市都要满足基金合同规定的仓位要求 ...

Group 1 - Two stock ETFs have recently announced their listing, with the Huaxia CSI Hong Kong Stock Connect Medical Theme ETF having a stock position of 24.51% and the Harvest CSI Hong Kong Stock Connect Innovative Drug ETF at 16.11% [1] - In the past month, a total of 28 stock ETFs have announced their listings, with an average position of 20.50%. The highest position is held by the Huitianfu National General Aviation Industry ETF at 42.30% [1][3] - The average number of shares raised for the newly announced ETFs is 460 million, with the leading funds being the Fortune CSI Hong Kong Stock Connect Technology ETF, Harvest CSI Hong Kong Stock Connect Innovative Drug ETF, and Southern Growth Enterprise Board Mid-Cap 200 ETF, raising 1.119 billion, 890 million, and 799 million shares respectively [1] Group 2 - The average proportion of shares held by institutional investors is 14.47%, with the highest proportions in the Huaxia CSI Hong Kong Stock Connect Medical Theme ETF (95.41%), Huitianfu National Hong Kong Stock Connect Consumer Theme ETF (85.50%), and Huaxia Shanghai Stock Exchange Selected Sci-Tech Innovation Board Value 50 Strategy ETF (36.38%) [2] - The ETFs with the lowest institutional investor holdings include the GF Shanghai Stock Exchange Sci-Tech Innovation Board 100 ETF (1.47%), Harvest Hong Kong Stock Connect Innovative Drug Selected ETF (1.85%), and Harvest CSI Hong Kong Stock Connect Innovative Drug ETF (2.13%) [2]

Institutional Movements - Long-term funds are continuously increasing their investments in the innovative drug sector amid recent market adjustments, indicating a long-term value in this sector, although a focus on quality companies is necessary due to previous strong price increases [1] Long-term Funds Entering via ETFs - Several newly launched innovative drug-themed ETFs have seen significant purchases from long-term funds this year, with Barclays Bank being a major holder of multiple ETFs, holding 20 million yuan in one and 85 million yuan in another [2] - Corporate pension plans have also heavily invested in innovative drug ETFs, with several plans holding over 40 million yuan each [2] - As of July 3, the Huatai-PineBridge Hang Seng Innovative Drug ETF has increased by over 60% since its launch, while the ICBC Credit Suisse National Index Hong Kong Innovative Drug ETF has risen nearly 30% [2] Fund Flows - The innovative drug-themed ETFs have attracted substantial net subscriptions, totaling nearly 9 billion yuan since June, with specific ETFs like the Huatai-PineBridge and GF Hong Kong Innovative Drug ETFs seeing net subscriptions of 4.44 billion yuan and 2.305 billion yuan, respectively [3] New Fund Launches - Public funds are increasing their focus on innovative drug-themed funds, with several new funds currently being issued, including the Xinyuan CSI Hong Kong Innovative Drug Index Fund and others set to launch soon [4] Long-term Outlook for the Innovative Drug Industry - The innovative drug sector in China is expected to continue its long-term positive trend, with significant overseas collaborations and clinical advancements being recognized by multinational pharmaceutical companies [5] - The recent rise in the innovative drug sector is attributed to a decade of accumulated competitive advantages rather than short-term market fluctuations, suggesting ongoing investment opportunities in quality innovative drug companies [5] - The industry is likely to experience linear development, while market performance may be more volatile, necessitating a focus on fundamental research and selective investment strategies [5]